



ESMO Asia 2017 Industry Satellite Symposium

Gastric Cancer Care: From evidence to practice

Chaired by Ian Chau

With Jae-Ho Cheong, Eva Segelov and Kohei Shitara

Friday 17th November, 12:45-14:15, Level 3 - Room 310
Suntec Singapore Convention and Exhibition Centre, Singapore

Contents

- 3 Programme**
- 3 Learning objectives**
- 4 Welcome message**
- 5 Faculty biographies**
Ian Chau
- 6 Faculty biographies**
Jae-Ho Cheong
- 7 Faculty biographies**
Eva Segelov
- 8 Faculty biographies**
Kohei Shitara
- 9 Symposium information**
- 10 Notes**

Programme

12:45-12:50	Welcome and introduction	Ian Chau Royal Marsden Hospital, UK
12:50-13:15	Proximal gastric cancer	Jae-Ho Cheong Yonsei University, Korea
13:15-13:40	Integrative molecular analysis of oesophago-gastric cancer: lessons learnt from colorectal cancer	Eva Segelov Monash University, Australia
13:40-14:05	Targeting the tumour microenvironment	Kohei Shitara National Cancer Center Hospital East, Japan
14:05-14:15	Faculty discussion and audience questions	All

Learning objectives

After attending the symposium, learners will be able to:

- Explain the current guidelines for peri-operative chemotherapy for Stage II/III proximal gastric cancer and how they will change in response to the new standards of care raised by trial data.
- Explain the use of molecular analysis in colorectal cancer, how it compares and contrasts with the current evidence base for gastric cancer, and how we can use developments in colorectal cancer to guide molecular analysis in gastric cancer.
- Discuss the evidence base supporting the current optimal therapeutic strategies for gastric cancer and how to implement these into a treatment plan during their daily practice and within the context of Asian patients.

Welcome message



Dear Colleagues,

Welcome to Singapore and thank you for joining us at 'Gastric Cancer Care: From evidence to practice', an independent satellite symposium at the ESMO Asia 2017 Congress.

With the success of the first two ESMO Asia congresses we hope to utilise this year's meeting, a unique assembly of Asia-Pacific oncology professionals and their international counterparts, to provide up-to-date education and a platform for invaluable international networking in the field of gastric cancer.

This symposium aims to discuss the latest in gastric cancer treatment and molecular analysis as well as to advise on how to incorporate the ever-changing current optimal therapeutic strategies into everyday clinical practice. We hope that by sharing the experience and perspectives of experts from Asia, Australia and Europe we can help delegates navigate the complexities of gastric cancer care and provide them with knowledge that they can seamlessly apply to their clinical practice.

Our objective is to make the session as interactive as possible to optimise educational outcomes and enable collaborative learning. We hope you find the content stimulating and that it will support you in keeping on top of the advances in this rapidly evolving field.

We would be grateful if you could take the time to feedback on this session by completing the evaluation form provided with this booklet.

Yours faithfully,

Ian Chau

Ian Chau – Chair

Faculty biographies



Ian Chau

(Symposium Chair)

Royal Marsden Hospital, UK

Dr Chau holds the position of Consultant Medical Oncologist within the Gastrointestinal and Lymphoma Units at the Royal Marsden Hospital and Honorary Senior Lecturer at the Institute of Cancer Research, London & Surrey. He qualified from the United Medical & Dental Schools of Guy's and St. Thomas' Hospitals, University of London, before undergoing medical oncology specialist training and clinical research fellowship at the Royal Marsden Hospital.

His main research interests are clinical trials and translational research in gastrointestinal cancers and lymphoma. He is the chief or principal investigator of multiple phase I, II and III clinical trials evaluating novel treatment strategies and agents in various cancer signalling pathways.

Dr Chau serves or has served on the American Society of Clinical Oncology (ASCO) Scientific Program Committee, ASCO Education Committee, European Society of Medical Oncology (ESMO) Congress Steering Committee, ESMO Asia Scientific Programme and Steering Committee, ESMO Educational Committee and UK National Cancer Research Institute (NCRI) Colorectal Cancer and Pancreatic Cancer Clinical Study Groups. He is on the Trial Management Groups and Trial Steering Groups of multiple national and global phase II-III gastrointestinal cancer and lymphoma trials. He serves or has served on the UK National Institute of Health and Care Excellence (NICE) Clinical Guideline Development Group for non-Hodgkin's Lymphoma and ASCO Management of Immune-mediated side effects Guideline Panel. He is the recipient of the Swedish Society of GI Oncology Bengt Glimelius Award 2016, merit awards from ASCO Gastrointestinal Cancer Symposium, The Royal Society of Medicine Section of Oncology Clinical Prize, fellowships from the European School of Oncology and ASCO / American Association for Cancer Research (AACR) / Federation of European Cancer Societies (FECS) Clinical Cancer Research Workshop.

Dr Chau has given invited lectures in over 30 countries, and has served on international drug development advisory boards. He has peer reviewed publications in *The New England Journal of Medicine*, *The Lancet*, *The Lancet Oncology*, *Journal of Clinical Oncology* and other leading oncology / biomedical journals.



Jae-Ho Cheong

Yonsei University, Korea

Professor Cheong practices as a surgeon–scientist, coming from a background in systems cancer biology, gastric cancer genomics and translational medicine. With more than 15 years of clinical experience in treating gastric cancer patients, he is now developing molecular diagnostics which are clinically usable to identify distinct prognostic and predictive subgroups to personalise treatment to the specific TNM stage. The overarching goal of his research is to identify potential diagnostic and therapeutic targets and to develop clinically relevant prognostic or predictive markers as well as valid targets for novel therapeutics.

To this end, he has been collaborating with a number of researchers in diverse disciplines such as cell biology, molecular biology, chemistry, bioinformatics, pathology and engineering. This trans-disciplinary approach utilises patient-derived resources to accurately model human cancer molecular pathophysiology to bridge the gap between pre-clinical studies and clinical practice. Currently, Professor Cheong and his colleagues have generated ~900 gastric cancer tissue multi-omics information which will serve a robust platform to achieve the goal of proposed research enterprise. In addition to clinical tumour repository, they have established ~40 fully molecularly characterised and clinically annotated patient-derived tumor xenograft (PDX) models. Based on these platforms, Pr Cheong develops novel cancer therapeutics specifically for therapy-refractory and stem-like subtype tumours.



Eva Segelov

Monash University, Australia

Professor Segelov was appointed Professor and Director of Oncology at Monash University and Monash Health, Melbourne, Victoria, in February 2017. Prior to this, she was Associate Professor of Medicine, University of New South Wales and Senior Medical Oncologist at St Vincent's Hospital, Sydney. She has specialist interest in the diagnosis and management of upper and lower gastrointestinal cancers, including neuroendocrine tumours and anal cancer.

Professor Segelov is the international lead on the ICECREAM and ASCOLT international trials and has been Australian lead on multiple studies. She has published over 70 articles, expert reviews and book chapters and is frequently an invited speaker at national and international conferences.

Professor Segelov is an ESMO faculty member for the CUP, Endocrine Tumours and Others group; member of the Editorial Board of Journal of Global Oncology (ASCO) 2015-present and the Track co-Chair, Gastrointestinal Cancer, ESMO Asia Annual Scientific Meeting 2017-9. In 2015 she co-founded the international research collaborative group CommNETS (Commonwealth Neuroendocrine Tumour Society).

Professor Segelov was awarded the University of New South Wales Vice Chancellor's Award for Teaching Excellence for developing flagship preceptorship programmes in multiple cancer subtypes, teaching the advent of modern cancer treatments through the understanding of seminal research papers. Eva is a Board member of the Australasian Gastro-Intestinal Trials Group (AGITG) and the Chair of Gastrointestinal Cancer of the Clinical Oncological Society of Australia (COSA).



Kohei Shitara

National Cancer Center, Hospital East, Japan

Dr Shitara is a Chief of Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa in Japan. He received his medical degree from Tohoku University School of Medicine in 2002.

Kohei Shitara is an active member of ASCO and ESMO. He is also a member of the Japanese Society of Internal Medicine, the Japanese Society of Medical Oncology (JSMO), the Japanese Society of Clinical Oncology (JSCO), the Japanese Gastric Cancer Association, Protocol Review Committee of Japanese Clinical Oncology Group (JCOG) and the West Japanese Oncology Group (WJOG). He also acts as one of the organising members for Japanese gastric cancer treatment guidelines.

His main research interests include the development of new anti-cancer agents, optimal chemotherapy regimens for gastrointestinal cancer, and translational research. Kohei Shitara is the primary investigator or study coordinator of several sponsor-initiated trials or investigator-initiated trials for gastric or colorectal cancer and acts as a steering committee member of five global studies in the field of GI cancers. He is also a study coordinator of the Nationwide Cancer Genome Screening Projects for Gastrointestinal Cancer in Japan (SCRUM-Japan GI-SCREEN).

Dr Shitara has contributed to 120 peer review publications, which include approximately 80 articles as first author or corresponding author in these fields.

Symposium information

Organisers

This educational activity has been planned and independently implemented by Springer Healthcare IME. Springer Healthcare IME is the Independent Medical Education group of Springer Healthcare, part of the Springer Nature publishing group.

Continuing Medical Education

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Imedex and Springer Healthcare IME.

Imedex is accredited by the ACCME to provide continuing medical education for physicians.

This activity has been approved for *AMA PRA Category 1 Credit™*.

Filming and photography

Springer Healthcare IME may film or take photographs at the symposium that may be used in publicity and marketing materials. Your attendance at the meeting may mean you are featured in such photographs and films and, unless you notify a member of the Springer Healthcare IME team of your objection to this, your consent will be implied.

Educational sponsorship

This programme is made possible thanks to independent educational sponsorship from Eli Lilly and Company.

Disclosure of Relevant Financial Relationships

As an accredited provider of continuing medical education, Imedex, LLC requires anyone in a position to affect the activity's subject matter to disclose any financial relationships they have as related to the contents of their presentations. The existence of commercial or financial interests of presenters related to the subject matter of their presentations should not be construed as implying bias or decreasing the value of their presentations. However, disclosure should help participants form their own judgments.

All presenters were independently selected by the organizers. Those presenters who disclosed affiliations or financial interests with the commercial organizations involved with products, to which they may refer, are listed below.

1=grant/research support 2=consultant 3=speaker's bureau 4=stock shareholder 5=other support

Ian Chau – Royal Marsden Hospital, UK: *Amgen¹, Bayer², Bristol-Myers Squibb², Eli Lilly^{1,2}, Five Prime Therapeutics², Janssen-Cilag¹, Merck-Serono¹, MSD², Novartis¹, Pfizer¹, Roche², Sanofi Oncology^{1,2}, Taiho¹*

Eva Segelov – Monash University, Australia: *Ipsen^{1,3}, Merck Serono^{1,2}, Roche^{1,5}, Shire^{1,3}*

Kohei Shitara – National Cancer Center Hospital East, Japan: *Eli Lilly Japan KK^{1,3}*

The following presenters do not report any financial relationships:

Jae-Ho Cheong – Yonsei University, Korea

Imedex, LLC Staff Disclosure of Financial Relationships

All Imedex staff members who are in a position to control content of this activity have no financial relationships with any commercial interests, except for the following individuals:

Chris Bolwell owns shares of stock of GlaxoSmithKline.

Imedex, LLC is an independent provider of continuing medical education. Imedex, LLC. has no proprietary or financial interest in medical or healthcare products over which the FDA (USA) or EMA (EU) has regulatory authority.

Unapproved and Investigational Uses of Drugs and Devices

This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters or moderators and do not necessarily reflect the opinions of Imedex.

Disclaimer

The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual's own physician.

Neither Imedex nor any of its subsidiaries or affiliates is affiliated with or formally endorsed by a medical society.

About Imedex

Imedex is a brand and assumed name used by Imedex, LLC (hereby referred to as Imedex). Imedex is solely responsible for this agenda's content. Although Imedex attempts to ensure that the information in our program is accurate and timely, matters and opinions discussed and/or presented with respect to clinical matters are those of the discussion participants only, and not necessarily those of Imedex. Moreover, although Imedex attempts to identify and integrate the most qualified medical professionals in our program, TO THE FULLEST EXTENT PERMITTED BY LAW, IMEDEX EXPRESSLY DISCLAIM ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES' RIGHTS, AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE CONTENT PRESENTED. IMEDEX FURTHER MAKES NO REPRESENTATIONS OR WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS OR TIMELINESS OF THE CONTENT OR ANY MATERIAL PRESENTED.

© 2017 Imedex, LLC. All rights reserved. Reproduction in whole or part is prohibited without prior written consent from Imedex and contributing faculty.



This independent programme is made possible thanks to educational sponsorship from Eli Lilly and Company